Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address: paul.martin@duke.edu

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987

Publications

Prasad, Vinod K., Juan Wu, Paul L. Martin, Timothy A. Driscoll, Suhag H. Parikh, Deborah Semmel, Jerelyn Moffet, et al. “Melphalan Containing Cytoreduction Results in a Good Overall Survival (OS) in Pediatric Patients with Relapse or Refractory AML Undergoing Unrelated Umbilical Cord Blood Transplantation (UCBT).” In Blood, 108:3150–3150. American Society of Hematology, 2006. https://doi.org/10.1182/blood.v108.11.3150.3150.

Full Text

Borowitz, Michael J., Meenakshi Devidas, W Paul Bowman, William L. Carroll, I-Ming Chen, Richard Harvey, Stephen Hunger, et al. “Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study.” In Blood, 108:219–219. American Society of Hematology, 2006. https://doi.org/10.1182/blood.v108.11.219.219.

Full Text

Lakshminarayanan, Sonali, Adam Mendizabal, Vinod Prasad, Suhag Parikh, Paul Szabolcs, Timothy Driscoll, Michelle Schweitzer, et al. “The Addition of Fludarabine to a Conventional Busulfan/Melphalan/Anti-Thymocyte Globulin (Flu/Bu/Mel/ATG) Preparative Regimen Increased Engraftment without Additional Toxicity.” Blood 108, no. 11 (November 16, 2006): 2944–2944. https://doi.org/10.1182/blood.v108.11.2944.2944.

Full Text

Martin, Paul L. “To stop or not to stop: how much support should be provided to mechanically ventilated pediatric bone marrow and stem cell transplant patients?” Respir Care Clin N Am 12, no. 3 (September 2006): 403–19. https://doi.org/10.1016/j.rcc.2006.06.002.

Full Text

Martin, P. L., T. A. Driscoll, P. Szabolcs, S. H. Parikh, V. K. Prasad, and J. Kurtzberg. “Busulfan/melphalan is an effective and well tolerated conditioning regimen for pediatric AML and MDS patients receiving a matched sibling BMT.” In Biology of Blood and Marrow Transplantation, 12:127–127. Elsevier BV, 2006. https://doi.org/10.1016/j.bbmt.2005.11.389.

Full Text

Lakshminarayanan, S., P. L. Martin, P. Szabolcs, T. Driscoll, S. Parikh, V. Prasad, and J. Kurtzberg. “Cellcept/cyclosporine as prophylaxis against graft- versus-host disease in pediatric patients undergoing allogeneic stem cell transplantation.” In Biology of Blood and Marrow Transplantation, 12:67–68. Elsevier BV, 2006. https://doi.org/10.1016/j.bbmt.2005.11.212.

Full Text

Guess, C., M. A. Frey, P. L. Martin, and J. Kurtzberg. “Patient controlled analgesia by proxy.” In Biology of Blood and Marrow Transplantation, 12:159–60. Elsevier BV, 2006. https://doi.org/10.1016/j.bbmt.2005.11.495.

Full Text

Martin, Paul L., Shelly L. Carter, Nancy A. Kernan, Indira Sahdev, Donna Wall, Daniel Pietryga, John E. Wagner, and Joanne Kurtzberg. “Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases.” Biol Blood Marrow Transplant 12, no. 2 (February 2006): 184–94. https://doi.org/10.1016/j.bbmt.2005.09.016.

Full Text

Prasad, V. K., J. Wu, S. H. Parikh, T. A. Driscoll, P. Szabolcs, P. L. Martin, S. Carter, and J. Kurtzberg. “Single center experience of unrelated umbilical cord blood transplantation (UCBDT) for acute myeloid leukemia (AML) in 97 pediatric patients: Impact of disease status and cytoreductive regimen.” In Biology of Blood and Marrow Transplantation, 12:124–124. Elsevier BV, 2006. https://doi.org/10.1016/j.bbmt.2005.11.381.

Full Text

Summers, E., J. Edmisten, P. L. Martin, M. Frey, and J. Kurtzberg. “Veno Occulsive disease: A potentially life threatening complication of hematopoietic stem cell transplantation.” In Biology of Blood and Marrow Transplantation, 12:161–161. Elsevier BV, 2006. https://doi.org/10.1016/j.bbmt.2005.11.500.

Full Text

Pages